ArcDia International Ltd, the Multianalyte Point-of-Care Company for Infectious Diseases, Strengthens Management
TURKU, Finland, April 11, 2013 /PRNewswire/ --
ArcDia International Ltd, the manufacturer of world's only multianalyte point-of-care diagnostic system for respiratory tract infections, is pleased to announce the strengthening of its management team and customer operations with the appointment of Jesper Floyd Kristiansen as VP Sales and Marketing.
Prior the appointment, Mr. Kristiansen held various management positions at Dako, the leading company for cancer diagnostics. He has worked as Business Director and Country Manager responsible for P&L and sales operations in the Central East Europe, Russia and Africa regions.
"ArcDia's mariPOC® is the first and only product on the market to allow efficient testing of infectious diseases at the point-of care. ArcDia has during the last couple of years participated in the most relevant trade fairs and congresses, and as late as January mariPOC® was presented at the Arab Health in Dubai with a huge interest from both potential distributors and end-users. I am excited to join the ArcDia team and to expand mariPOC® business in the international markets", says Jesper Kristiansen, VP Sales and Marketing, ArcDia Ltd.
"We are pleased to welcome Mr. Kristiansen to join the ArcDia team. He brings his experience and knowledge in international sales of IVD products to build up the distribution channels and customer operations for the mariPOC® product line", says Dr. Aleksi Soini, CEO of ArcDia Ltd.
Earlier in 2012, ArcDia announced collaboration agreement with Laboratories LETI for Spain and Portugal. ArcDia's products have been in daily clinical practice since 2011.
mariPOC® provides multianalyte diagnostic results for influenza like illnesses and tonsillitis in near patient settings in 20 minutes. The mariPOC® applications are targeted to acute respiratory infections, which represents the most common infectious diseases on Earth.
mariPOC® is superior in performance to the conventional test methods, including lateral flow rapid tests and standard culturing. mariPOC® is designed to improve patient management, quality of health care, and to allow pathogen specific timely diagnostics and medication to all patients. mariPOC® was launched to the European market in late 2010.
ArcDia International Ltd is the manufacturer of mariPOC®, world's first multianalyte point-of-care diagnostics test for respiratory tract infections. In the future, the company will develop additional point-of-care tests based on its proprietary ArcDia™ TPX detection technology (Nature Biotech 2000:18). The technology is available for prominent industrial parties for in-licensing. Currently, ArcDia is actively seeking distribution partners for mariPOC®. http://www.arcdia.com
SOURCE ArcDia International Ltd